Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 908 Devices Inc.MASS · Entity 5564 | Director | June 10, 2026 | June 12, 2026 |
| REPLIGEN CORPRGEN · Entity 486 | Director | March 02, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
908 Devices Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,168 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Exercise / conversion · Acquired 14,083 · Balance 44,168 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Exercise / conversion · Disposed 14,083 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,656 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Grant · Acquired 13,656 · Balance 13,656 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. |
| Stock Option (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.22 · Expires 2036-06-10 | Direct | 6,209 |
Reported balance
After 2026-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-11 · Grant · Acquired 6,209 · Balance 6,209 F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date.
F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date.
F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date.
REPLIGEN CORP
Report date March 02, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 89,062 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Tax withholding · Disposed 9,897 · Balance 89,062 F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Disposition to issuer · Disposed 15,046 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2024 Filed Mar 1, 2024 02:04 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 19,719 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023489 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,026 F1 · shares: Mr. Hunt was awarded 19,719 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-064504 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,307 F1 · kind: The shares were disposed of in connection with a bona fide gift by the Reporting Person to a donor advised fund. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:52 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantStock Option (option to buy) · Derivative | 12,076 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0001562180-23-005308 · primarydocument.xml · derivative · entry 4 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,076 Underlying: Common Stock · 12,076 shares Expires 2033-06-15 F5 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 15, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:52 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantRestricted Stock Units · Derivative | 7,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005308 · primarydocument.xml · derivative · entry 3 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,777 Underlying: Common Stock · 7,777 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F4 · derivative.exercise_date: The RSUs become fully vested on June 15, 2024 or the day prior to the 2024 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs become fully vested on June 15, 2024 or the day prior to the 2024 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:52 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionRestricted Stock Units · Derivative | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005308 · primarydocument.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date. F2 · derivative.exercise_date: The RSUs became fully vested on June 14, 2023, the day prior to the 2023 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs became fully vested on June 14, 2023, the day prior to the 2023 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:52 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionCommon Stock | 4,771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-23-005308 · primarydocument.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 22:23 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 8,244 | $188.00 | $1,549,872.00 |
DisclosureSEC source: 0000899243-23-007194 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,307 F3 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the settlement of the PSUs. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 22:23 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 18,584 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007194 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,551 F2 · shares: Represents 18,584 shares issued pursuant to a Performance Stock Unit ("PSU") award granted to the Issuer on February 27, 2020. The Compensation Committee authorized the issuance of the underlying shares based upon the Issuer's achievement of pre-established performance criteria set forth in the PSU award. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 00:47 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 6,670 | $176.37 | $1,176,387.90 |
DisclosureSEC source: 0000899243-23-006772 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,574 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 22:23 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 20,080 | $0.00 Strike: $180.48 | $0.00 |
DisclosureSEC source: 0000899243-23-007194 · doc4.xml · derivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,080 Underlying: Common Stock · 20,080 shares Expires 2033-03-02 F4 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on March 2, 2024, March 2, 2025 and March 2, 2026. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 22:23 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 19,393 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007194 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,967 F1 · shares: Mr. Hunt was awarded 19,393 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 21:20 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionRestricted Stock Unit · Derivative | 2,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002561 · primarydocument.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,115 Underlying: Common Stock, par value $0.001 · 6,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 3 years following March 2, 2022, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 3 years following March 2, 2022, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 21:20 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionCommon Stock, par value $0.001 | 2,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-23-002561 · primarydocument.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 00:53 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 3,273 | $173.44 | $567,669.12 |
DisclosureSEC source: 0000899243-23-006512 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,992 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:47 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 2,748 | $173.28 | $476,173.44 |
DisclosureSEC source: 0000899243-23-006772 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,244 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 22:43 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0000899243-22-035725 · doc4.xml · derivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,246 Underlying: Common Stock · 25,000 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 22:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 25,000 | $200.00 | $5,000,000.00 |
DisclosureSEC source: 0000899243-22-035725 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,265 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 14, 2021. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 22:43 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 25,000 | $33.87 | $846,750.00 |
DisclosureSEC source: 0000899243-22-035725 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:14 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0000899243-22-030727 · doc4.xml · derivative · entry 10 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,246 Underlying: Common Stock · 10,000 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 245 | $227.01 | $55,617.45 |
DisclosureSEC source: 0000899243-22-030727 · doc4.xml · nonDerivative · entry 9 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,265 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 14, 2021. F9 · price: $227.01 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $226.98 to $227.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,873 | $226.34 | $1,102,954.82 |
DisclosureSEC source: 0000899243-22-030727 · doc4.xml · nonDerivative · entry 8 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,510 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 14, 2021. F8 · price: $226.34 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.94 to $226.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 10,490 | $225.22 | $2,362,557.80 |
DisclosureSEC source: 0000899243-22-030727 · doc4.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,383 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 14, 2021. F7 · price: $225.22 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.91 to $225.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 6,626 | $224.47 | $1,487,338.22 |
DisclosureSEC source: 0000899243-22-030727 · doc4.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,873 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 14, 2021. F6 · price: $224.47 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.91 to $224.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,389 | $223.26 | $310,108.14 |
DisclosureSEC source: 0000899243-22-030727 · doc4.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,499 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 14, 2021. F5 · price: $223.26 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.90 to $223.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 720 | $222.24 | $160,012.80 |
DisclosureSEC source: 0000899243-22-030727 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,888 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 14, 2021. F4 · price: $222.24 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.87 to $222.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,235 | $221.46 | $273,503.10 |
DisclosureSEC source: 0000899243-22-030727 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,608 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 14, 2021. F3 · price: $221.46 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.86 to $221.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 824 | $220.08 | $181,345.92 |
DisclosureSEC source: 0000899243-22-030727 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,843 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 14, 2021. F2 · price: $220.08 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.42 to $220.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:14 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 10,000 | $33.87 | $338,700.00 |
DisclosureSEC source: 0000899243-22-030727 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2022 Filed Jul 22, 2022 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,154 | $0.00 Strike: $32.40 | $0.00 |
DisclosureSEC source: 0000899243-22-026581 · doc4.xml · derivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,154 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 21, 2022 Filed Jul 22, 2022 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0000899243-22-026581 · doc4.xml · derivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,246 Underlying: Common Stock · 5,000 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 21, 2022 Filed Jul 22, 2022 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 24,802 | $200.00 | $4,960,400.00 |
DisclosureSEC source: 0000899243-22-026581 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,667 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 14, 2021. Read SEC document |
| July 21, 2022 Filed Jul 22, 2022 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 15,154 | $32.40 | $490,989.60 |
DisclosureSEC source: 0000899243-22-026581 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2022 Filed Jul 22, 2022 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 5,000 | $33.87 | $169,350.00 |
DisclosureSEC source: 0000899243-22-026581 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:18 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantStock Option (option to buy) · Derivative | 7,970 | $0.00 Strike: $14.15 | $0.00 |
DisclosureSEC source: 0001562180-22-005196 · primarydocument.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,970 Underlying: Common Stock, par value $0.001 · 7,970 shares Expires 2032-06-16 F3 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 16, 2022, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:18 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantRestricted Stock Unit · Derivative | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005196 · primarydocument.xml · derivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,771 Underlying: Common Stock, par value $0.001 · 4,771 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2 · derivative.exercise_date: The RSUs become fully vested on June 16, 2023 or the day prior to the 2023 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs become fully vested on June 16, 2023 or the day prior to the 2023 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:19 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantRestricted Stock Unit · Derivative | 10,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-002374 · primarydocument.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,362 Underlying: Common Stock, par value $0.001 · 10,362 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 3 years following March 2, 2022, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 3 years following March 2, 2022, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:19 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantStock Option (option to buy) · Derivative | 6,173 | $0.00 Strike: $16.20 | $0.00 |
DisclosureSEC source: 0001562180-22-002374 · primarydocument.xml · derivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,173 Underlying: Common Stock, par value $0.001 · 6,173 shares Expires 2032-03-02 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following March 2, 2022, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 20:52 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 7,292 | $194.06 | $1,415,085.52 |
DisclosureSEC source: 0000899243-22-009046 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,315 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:49 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 13,368 | $196.70 | $2,629,485.60 |
DisclosureSEC source: 0000899243-22-008750 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,607 F3 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the settlement of the PSUs. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:49 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 30,074 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-008750 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,975 F2 · shares: Represents shares issued pursuant to a Performance Stock Unit ("PSU") award granted to the Issuer on February 28, 2019. The Compensation Committee authorized the issuance of the underlying shares based upon the Issuer's achievement of pre-established performance criteria set forth in the PSU award. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:49 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 3,170 | $196.70 | $623,539.00 |
DisclosureSEC source: 0000899243-22-008750 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,901 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 00:49 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 2,754 | $196.70 | $541,711.80 |
DisclosureSEC source: 0000899243-22-008750 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,071 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 01:04 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 20,307 | $0.00 Strike: $189.21 | $0.00 |
DisclosureSEC source: 0000899243-22-008191 · doc4.xml · derivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,307 Underlying: Common Stock · 20,307 shares Expires 2032-02-24 F4 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 24, 2023, February 24, 2024 and February 24, 2025. Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 01:04 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 1,170 | $189.21 | $221,375.70 |
DisclosureSEC source: 0000899243-22-008191 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,825 F3 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 01:04 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 15,855 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-008191 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,995 F1 · shares: Mr. Hunt was awarded 15,855 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. F2 · balance_after: The total reported in Column 5 has been adjusted to correct an overstatement of total holdings by 1,000 shares, first reflected in a Form 5 filed on February 10, 2021. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:45 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $32.40 | $0.00 |
DisclosureSEC source: 0000899243-21-045407 · doc4.xml · derivative · entry 9 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,154 Underlying: Common Stock · 10,000 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:45 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 596 | $281.40 | $167,714.40 |
DisclosureSEC source: 0000899243-21-045407 · doc4.xml · nonDerivative · entry 8 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,140 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F8 · price: $281.40 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.13 to $281.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:45 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 970 | $279.08 | $270,707.60 |
DisclosureSEC source: 0000899243-21-045407 · doc4.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,736 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F7 · price: $279.08 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $278.58 to $279.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:45 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 6,024 | $278.08 | $1,675,153.92 |
DisclosureSEC source: 0000899243-21-045407 · doc4.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,706 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F6 · price: $278.08 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.58 to $278.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:45 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,732 | $277.01 | $479,781.32 |
DisclosureSEC source: 0000899243-21-045407 · doc4.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,730 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F5 · price: $277.01 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.56 to $277.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.